Financing
Delix raises $100 million Series C to move zalsupindole into Phase IIb depression study
JJDC and the Dementia Discovery Fund led the round. The money funds a Phase IIb proof-of-concept trial of the neuroplastogen in recurrent major depressive disorder, due to begin in early 2027. In a Phase Ib study, depression scores fell about 50% on average after a week.
- Drugzalsupindole
- CompanyDelix Therapeutics
- TargetSerotonin receptor 5-HT2A
- Target5-hydroxytryptamine receptor 2B
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.